Investigations
A detailed family, physiological, pharmacological, past and recent medical history was collected for each patient through the medical reports of their first endocrinological examination following the appearance of pubertal signs: the time of onset of the first signs of pubertal development was retrieved in order to derive the age at puberty onset: as a surrogate for such information, the time when parents became aware of the onset of their children’s first pubertal signs was used. Whenever possible, the age of maternal menarche and patients’ weight at birth were also retrieved. In addition, the presence of any previous or ongoing acute or chronic disease and any drug treatment at the time of the first visit was also investigated; we also took into account whether or not patients were started on treatment with GnRH analogues after the diagnosis of CPP was made. Finally, the time (in days) between the onset of the first pubertal signs and the day the diagnosis of CPP was made (as in the day on which LH values—either basal or dynamic—were found suggestive of CPP) was calculated for each patient.
All patients underwent a thorough auxological and physical examination: the stage of pubertal progression according to Tanner score system, weight, height, BMI, and target height were measured. Height was measured to the nearest tenth of a centimeter using a Harpenden Stadiometer; in patients for whom height measurements prior to the first clinical evaluation were also available, growth velocity (expressed as an increase in centimeters of height in one year) was also calculated. Weight was determined to the nearest tenth of a kilogram using an electronic scale. BMI was also obtained. Target height was calculated except in adopted children. Height, BMI, target height, and growth velocity were all adjusted for chronological age by conversion to SDS (Standard Deviation Score): standard deviations (SD) derived from World Health Organization (WHO) curves were used for BMI; different curves were used for height according to the nationality of each patient: for patients whose parents were both Italian, Italian Cacciari’s curves were used, while for patients who had either one or both parents of foreign origins, WHO curves were used. Finally, the difference in SDS between patient's height and their respective target height (when available) was also calculated.
Blood samples for baseline biochemical assessment were taken fasting and within a time window between 7 a.m. and 10 a.m. Basal LH (U/L), FSH (U/L) and 17β-estradiol (pmol/L) were measured in all patients, using ECLIA (ElectroChemiLuminescence ImmunoAssay) methodology (ELECSYS® technology, Roche Diagnostic). Both LH and FSH assays have a quantification range that goes from 0.1 to 200 U/L, with a lower limit of detection of 0.1 U/L. Whenever available, the levels of other hormones were also collected: total testosterone (nmol/L), delta-4-androstenedione (mcg/L), DHEAS (mg/L), 17-OHP (mcg/L), IGF1 (mcg/L), prolactin (ng/ml), ACTH (ng/L), cortisol (mcg/dL), TSH (mU/L), FT4 (pmol/L) and FT3 (pmol/L). Due to the retrospective nature of our study, the levels of such analytes were not available in all patients and they were sometimes measured in different laboratories using different assay methods. Listed in Supplementary Table 1 is the number of patients in whom it was possible to retrieve such values.
All values of LH, FSH and estradiol included in the data analysis dated back to the day GnRH-test was performed; whenever possible, the same was done for the other analytes as well, otherwise these values were retrieved from earlier samplings, as close as possible to the date on which the GnRH test was performed.
Furthermore, considering the different reference ranges used by different laboratories for the assays of IGF-1, DHEAS, and delta-4-androstenedione and the different reference ranges of IGF-1 according to age, for each of the three analytes the ratio between such values and their respective upper reference limit was calculated and included in the data analysis.
A dynamic assessment of the hypothalamic-pituitary–gonadal axis was performed through GnRH testing: after collecting the Informed Consent from either parent, a peripheral venous catheter was placed within the patient’s mid upper arm (fasting) and a bolus of 100 µg gonadorelin (Relefact® 0.1 mg) was administered intravenously. Blood samples for the measurement of LH and FSH were taken every 30 min (0′; 30′; 60′; 90′; 120′). Basal or post-stimulus LH values above 5 U/L were considered indicative of central precocious puberty. In addition, we aimed to define two further surrogate parameters to investigate the degree of central pubertal activation in our patients: ΔLH and ΔFSH, both in absolute terms and as percentages, were calculated as the difference between LH and FSH peaks and their respective basal values; furthermore LH/FSH ratio was calculated as the proportion of these hormones both at baseline and at their peak.
Bone age was assessed through an X-ray of the left hand and wrist and was then calculated using either Tanner-Whitehouse 3 or Greulich and Pyle method. The difference between bone age and chronological age was then derived for each patient, and it was recorded in both absolute terms and as percentages.
Transabdominal pelvic ultrasonography was performed in order to collect the size and characteristics of uterus and ovaries. Since longitudinal diameter was the only one to be measured in every sonographic evaluation of the uterus, it was the only one that was finally included in our data analysis; in addition, whenever they were available, endometrial thickness and ovarian volume were also collected; ovarian volume was calculated using the ellipsoid formula (longitudinal diameter x transverse diameter x sagittal diameter × 0. 5233).
Neuroradiological study of the hypothalamic-pituitary region was carried out through a high-resolution nuclear magnetic resonance, both under basal conditions and after administration of intravenous paramagnetic contrast agent. The magnetic field strength used was 1.5 T, with a matrix of 250 × 256. Coronal sections were taken as thick as 2 mm, extending from the posterior wall of the frontal sinus to the sellar tubercle (under basal conditions) and from the tubercle to the sellar dorsum (following the administration of the paramagnetic contrast agent).
The genetic analysis aimed at searching for rare allelic variants that could explain the onset of CPP was performed through a Next Generation Sequencing (NGS) technique using MiSeq® Illumina technology. The panel of candidate genes associated with central precocious puberty that were investigated included the following: MKRN3, GnRH1, GnRH2, GnRHR, KISS1, KISS1R, TAC3 and TACR3.